Literature DB >> 11361459

Characteristics of children surviving to 5 years of age or older with vertically acquired HIV infection.

M W Kline1, M E Paul, B Bohannon, C A Kozinetz, W T Shearer.   

Abstract

The objective of this study was to examine characteristics of long-term survivors (aged 5 years or older) of vertical human immunodeficiency virus (HIV) infection. A retrospective cohort study design was employed. Forty-eight (68%) of 71 children who were born before 1990 and evaluated in our center survived to at least 5 years of age; 41 (58%) children remain alive (median age, 7.3 years). Only one (11%) of nine children with initial acquired immunodeficiency syndrome (AIDS)-defining conditions in the first year of life survived to age 5, whereas 47 (76%) of 62 children who did not have AIDS by age 1 year were alive at 5 years of age (p = .0003). Seventeen (43%) of 40 children with AIDS-defining conditions before age 5, and all 31 children without such conditions, survived to age 5 years (p = .000001). All eight children with lymphoid interstitial pneumonitis/pulmonary lymphoid hyperplasia (LIP/PLH) as their sole AIDS-defining condition survived to age 5. All 24 children who had neither an AIDS-defining condition nor severe immunosuppression by 5 years of age, and 24 (51%) of 47 children who had either or both of these findings, survived to age 5 years (p = .00008). To date, only 16 (39%) of 41 surviving children older than 5 years of age have had an AIDS-defining condition. However, true nonprogression of HIV disease (no clinical signs or symptoms; no evidence of immunosuppression) was unusual, occurring in only two (5%) of the same 41 children. In our center, most children with vertical HIV infection survive to at least 5 years of age, but the prognosis is not as good for those who experience an AIDS-defining condition or severe immunosuppression in the first 5 years of life.

Entities:  

Mesh:

Year:  1995        PMID: 11361459

Source DB:  PubMed          Journal:  Pediatr AIDS HIV Infect        ISSN: 1045-5418


  5 in total

1.  Long-term follow-up of children in the HIVNET 012 perinatal HIV prevention trial: five-year growth and survival.

Authors:  Maxensia Owor; Anthony Mwatha; Deborah Donnell; Philippa Musoke; Francis Mmiro; Melissa Allen; J Brooks Jackson; Mary Glenn Fowler; Laura A Guay
Journal:  J Acquir Immune Defic Syndr       Date:  2013-12-15       Impact factor: 3.731

2.  Alterations in cardiac and pulmonary function in pediatric rapid human immunodeficiency virus type 1 disease progressors. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted Human Immunodeficiency Virus Study Group.

Authors:  W T Shearer; S E Lipshultz; K A Easley; K McIntosh; J Pitt; T C Quinn; M Kattan; J Goldfarb; E Cooper; Y Bryson; A Kovacs; J T Bricker; H Peavy; R B Mellins; N Heart; L B Institute
Journal:  Pediatrics       Date:  2000-01       Impact factor: 7.124

3.  Type 1 and type 2 cytokine profiles in children exposed to or infected with vertically transmitted human immunodeficiency virus.

Authors:  B N Lee; J G Lu; M W Kline; M Paul; M Doyle; C Kozinetz; W T Shearer; J M Reuben
Journal:  Clin Diagn Lab Immunol       Date:  1996-09

4.  Prospective 5-year study of peripheral blood CD4, CD8, and CD19/CD20 lymphocytes and serum Igs in children born to HIV-1 women. The P(2)C(2) HIV Study Group.

Authors:  W T Shearer; K A Easley; J Goldfarb; H M Rosenblatt; H B Jenson; A Kovacs; K McIntosh
Journal:  J Allergy Clin Immunol       Date:  2000-09       Impact factor: 10.793

5.  Evaluation of immune survival factors in pediatric HIV-1 infection.

Authors:  W T Shearer; K A Easley; J Goldfarb; H B Jenson; H M Rosenblatt; A Kovacs; K McIntosh
Journal:  Ann N Y Acad Sci       Date:  2000-11       Impact factor: 5.691

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.